High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting.
High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting.
复制标题
DOI：
10.1371/journal.pone.0140985
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Bergh A
中科院分区：
文献类型：
--
作者：
Nilsson M;Hägglöf C;Hammarsten P;Thysell E;Stattin P;Egevad L;Granfors T;Jernberg E;Wikstrom P;Halin Bergström S;Bergh A
赖氨酰氧化酶（LOX）已被证明可以促进和抑制肿瘤进展，但其在前列腺癌中的作用在很大程度上是未知的。LOX免疫反应性在前列腺肿瘤上皮、肿瘤间质和肿瘤邻近的非恶性前列腺上皮和间质中进行评分。然后检查肿瘤和非恶性前列腺组织中LOX评分与经尿道切除术诊断为前列腺癌并随后观察等待的男性历史队列的临床特征和生存率的可能关联。在非恶性前列腺上皮中LOX评分低的男性比LOX评分高的男性具有显著更长的癌症特异性生存期。此外，在包括Gleason评分在内的多变量分析中，非恶性前列腺上皮的LOX评分仍具有预后性。前列腺肿瘤上皮中LOX评分与Gleason评分和转移呈正相关，但与癌症生存率无关。肿瘤和非恶性前列腺间质中的LOX评分似乎与这些肿瘤特征无关。在根治性乳腺癌切除术标本中，LOX免疫染色对应LOX原位杂交和LOX mRNA水平被发现是相似的肿瘤和相邻的非恶性区域之间，但骨转移样本显着增加。肿瘤和周围肿瘤器官中的LOX水平显然与前列腺癌的侵袭性有关。
Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium, tumor stroma and in the tumor-adjacent non-malignant prostate epithelium and stroma. LOX scores in tumor and non-malignant prostate tissues were then examined for possible associations with clinical characteristics and survival in a historical cohort of men that were diagnosed with prostate cancer at transurethral resection and followed by watchful waiting. Men with a low LOX score in the non-malignant prostate epithelium had significantly longer cancer specific survival than men with a high score. Furthermore, LOX score in non-malignant prostate epithelium remained prognostic in a multivariable analysis including Gleason score. LOX score in prostate tumor epithelium positively correlated to Gleason score and metastases but was not associated with cancer survival. LOX score in tumor and non-malignant prostate stroma appeared unrelated to these tumor characteristics. In radical prostatectomy specimens, LOX immune-staining corresponded to LOX in-situ hybridization and LOX mRNA levels were found to be similar between tumor and adjacent non-malignant areas, but significantly increased in bone metastases samples. LOX levels both in tumors and in the surrounding tumor-bearing organ are apparently related to prostate cancer aggressiveness.